Zenpep market forecast points to steady global growth through 2035
The Business Research Company says the Zenpep market is set to expand through 2035, driven by higher rates of pancreatic disorders, rising awareness of gastrointestinal disease and an aging population. North America led the market in 2025, while specialty pharmacy growth and improved enzyme therapies are expected to support demand.
Why it matters: - Zenpep demand is tied to conditions that affect digestion, nutrient absorption and long-term patient care. - The market outlook matters for drug makers, specialty pharmacies and clinicians treating exocrine pancreatic insufficiency. - Growth in EPI diagnosis and treatment could expand access for both pediatric and adult patients.
What happened: - The Business Research Company published a Zenpep market report covering market size, trends and a global forecast for 2026 to 2035. - The report says the Zenpep market expanded during the historical period because of rising cystic fibrosis prevalence, advances in pancrelipase formulations, broader gastroenterology care, better awareness of exocrine pancreatic insufficiency and early adoption of enzyme therapies. - The report expects future growth from demand for long-term digestive support, more personalized dosing, wider access to EPI therapies, specialty pharmacy distribution and enzyme delivery innovation. - The report says North America was the largest regional Zenpep market in 2025.
The details: - Zenpep, or pancrelipase, is a prescription drug used to treat exocrine pancreatic insufficiency caused by cystic fibrosis, chronic pancreatitis and other pancreatic diseases. - The medicine contains lipase, protease and amylase, which help break down fats, proteins and carbohydrates. - The report identifies pancreatic disorders as a major growth driver for the market. - Pancreatic disorders include inflammation, cancer and enzyme imbalances that can disrupt blood sugar regulation and digestion. - Rising obesity, poor diet, high alcohol use, smoking and genetic predisposition are among the factors linked to more pancreatic disorders. - Zenpep supports enzyme replacement therapy and can help reduce symptoms such as malnutrition and digestive discomfort. - NHS England reported in August 2024 that cystic fibrosis affects about 9,259 people in England and 11,148 across the UK. - The report also links market growth to greater awareness of gastrointestinal disorders. - The ME Association reported in April 2024 that roughly 10% to 15% of the UK population has irritable bowel syndrome, and 35% to 70% of people with fibromyalgia also have IBS. - The report says an aging population is another driver because older adults produce fewer digestive enzymes and may need more digestive support. - The Population Reference Bureau said in January 2024 that the number of Americans age 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050. - That same projection puts the share of the U.S. population age 65 and older at 23% in 2050, up from 17% in 2022. - The report breaks out regional coverage across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.
Between the lines: - The market story is less about one drug and more about the broader shift toward diagnosing and managing chronic digestive conditions earlier. - Specialty pharmacy distribution and adherence tools suggest the market is moving toward more sustained, patient-specific treatment models. - The emphasis on formulation stability and delivery technology points to competition around usability, not just clinical need.
What's next: - The report expects wider use of enzyme replacement therapies and better detection of EPI to support demand through 2035. - Improved patient adherence programs and future delivery technologies may shape how Zenpep is prescribed and distributed. - The report also says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards and hotspot infographics. - More information is available in the full report and a free sample.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
American Business Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.